DRIVEN

Our lead program, THB335, is a potent and highly selective, oral small molecule inhibitor of KIT, a master regulator of mast cell function and survival. Mast cells have long been known to be a central driver of allergic and inflammatory processes. By inhibiting KIT, THB-335 is expected to inactivate and deplete mast cells, providing the potential for broad symptomatic relief across a range of inflammatory diseases.